Mr. Alejandro Antalich reports

BIOMIND LABS ANNOUNCES LISTING ON THE CANADIAN SECURITIES EXCHANGE AND THE DELISTING FROM THE CBOE CANADA

Biomind Labs Inc. has received approval to list its common shares on the Canadian Securities Exchange, and the common shares will commence trading on the CSE at market open on Aug. 11, 2026, under the symbol BMND. In connection with the listing of the common shares on the CSE, the company will be delisting its common shares from the Cboe Canada, effective close of business on Aug. 10, 2026. Both the CSE and Cboe will issue bulletins in connection with the respective listing and delisting of the common shares.

No action is required from shareholders in connection with this change in listing, and the company's OTC Pink listing is unaffected by this change.

Management is excited about the listing of the common shares on the CSE and the opportunities it provides to investors, as the company continues to develop its business operations. The company wishes to express its sincere gratitude to Cboe Canada and its management team for their support and partnership over the five years. Biomind values the role Cboe Canada played in supporting the company during its early stage of development and looks forward to its next chapter on the CSE.

About Biomind Labs Inc.

Biomind Labs is a clinical-stage biopharmaceutical company focused on transforming breakthroughs in neuroscience and biomedical research into novel pharmaceutical drugs and proprietary nanotechnology-based delivery systems for psychiatric and neurological conditions that affect the central nervous system. Leveraging translational neuroscience and formulation science, Biomind aims to optimize the pharmacological profile of key endogenous and naturally derived molecules to address unmet needs in the CNS therapeutics. The company is committed to rigorous clinical validation and patient-centric innovation.

We seek Safe Harbor.